UBS Asset Management Americas Inc. lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 72.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 72,521 shares of the medical device company’s stock after selling 194,226 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in DexCom were worth $4,162,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its position in DexCom by 29.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock valued at $431,510,000 after buying an additional 1,991,094 shares in the last quarter. Brown Advisory Inc. grew its position in DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock valued at $203,798,000 after buying an additional 1,515,134 shares in the last quarter. JPMorgan Chase & Co. grew its position in DexCom by 143.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock valued at $107,170,000 after buying an additional 7,738,678 shares in the last quarter. AXA grew its position in DexCom by 10.5% in the 3rd quarter. AXA now owns 1,318,931 shares of the medical device company’s stock valued at $64,529,000 after buying an additional 124,920 shares in the last quarter. Finally, Mackenzie Financial Corp grew its position in DexCom by 14.0% in the 3rd quarter. Mackenzie Financial Corp now owns 1,283,747 shares of the medical device company’s stock valued at $62,807,000 after buying an additional 157,962 shares in the last quarter.

How to Become a New Pot Stock Millionaire

DexCom, Inc. (NASDAQ DXCM) opened at $64.91 on Wednesday. DexCom, Inc. has a 12-month low of $42.62 and a 12-month high of $86.32. The company has a current ratio of 5.36, a quick ratio of 5.04 and a debt-to-equity ratio of 0.78.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.07. DexCom had a negative net margin of 6.99% and a negative return on equity of 13.99%. The company had revenue of $221.00 million during the quarter, compared to analyst estimates of $217.82 million. analysts expect that DexCom, Inc. will post -0.57 earnings per share for the current fiscal year.

In other DexCom news, insider Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total transaction of $568,600.00. Following the completion of the sale, the insider now directly owns 484,559 shares of the company’s stock, valued at $27,552,024.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction dated Tuesday, December 26th. The shares were sold at an average price of $56.39, for a total transaction of $92,197.65. Following the sale, the executive vice president now directly owns 65,049 shares of the company’s stock, valued at $3,668,113.11. The disclosure for this sale can be found here. Insiders have sold 24,908 shares of company stock valued at $1,401,535 over the last ninety days. Insiders own 1.70% of the company’s stock.

A number of equities analysts recently issued reports on the stock. Piper Jaffray Companies reiterated a “buy” rating on shares of DexCom in a research report on Monday. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. ValuEngine lowered shares of DexCom from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Northcoast Research reiterated a “buy” rating on shares of DexCom in a research report on Sunday, March 4th. Finally, Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “sell” rating in a research report on Friday, March 2nd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $65.97.

TRADEMARK VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/03/14/ubs-asset-management-americas-inc-has-4-16-million-position-in-dexcom-inc-dxcm.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.